RALOXIFENE DIN 02415852
Health Canada record
| Active ingredient(s) | RALOXIFENE HYDROCHLORIDE 60 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | G03XC01 RALOXIFENE |
| Original market date | 28-Nov-2013 |
| Current status date | 26-Apr-2018 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pro Doc Limitée — licence 100182, currently licensed, last inspection rating C (2025-08-11).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RALOXIFENE HYDROCHLORIDE
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02358840 | ACT RALOXIFENE | TEVA CANADA LIMITED | Tablet | RALOXIFENE HYDROCHLORIDE 60 MG | Marketed |
| 02279215 | APO-RALOXIFENE | APOTEX INC | Tablet | RALOXIFENE HYDROCHLORIDE 60 MG | Marketed |
| 02540681 | JAMP RALOXIFENE | JAMP PHARMA CORPORATION | Tablet | RALOXIFENE HYDROCHLORIDE 60 MG | Marketed |
| 02239028 | EVISTA | ELI LILLY CANADA INC | Tablet | RALOXIFENE HYDROCHLORIDE 60 MG | Cancelled Post Market |
| 02358921 | PMS-RALOXIFENE | PHARMASCIENCE INC | Tablet | RALOXIFENE HYDROCHLORIDE 60 MG | Cancelled Post Market |
| 02312298 | TEVA-RALOXIFENE | TEVA CANADA LIMITED | Tablet | RALOXIFENE HYDROCHLORIDE 60 MG | Cancelled Post Market |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 14942 | 2013-11-26 | Abbreviated New Drug Submission (ANDS) | LICENSING AGREEMENT BETWEEN TWO COMPANIES |
International API supply for RALOXIFENE HYDROCHLORIDE
10 valid EDQM Certificates of Suitability from 10 holders. 14 active FDA Drug Master Files.
Request a quote for RALOXIFENE